Analysed AKESO INC (AKESF:OTCMKTS) News Sources
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
15-09-2026
yahoo.com
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
17-09-2026
yahoo.com
Is Akeso (SEHK:9926) Cheap As Its New Trial Clearance Puts Valuation Back In Focus?
19-09-2026
yahoo.com
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
21-09-2026
yahoo.com
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
28-09-2026
yahoo.com
What is the current price of AKESO INC (AKESF:OTCMKTS)?
The current price of AKESO INC (AKESF:OTCMKTS) is $14.543.
AKESO INC (AKESF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of AKESO INC (AKESF:OTCMKTS) since the previous trading day is $0.743.
AKESO INC (AKESF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of AKESO INC (AKESF:OTCMKTS) since the previous trading day is 5.3841%.
What is the most recent average sentiment score for AKESO INC (AKESF:OTCMKTS)?
The most recent average sentiment score for AKESO INC (AKESF:OTCMKTS) is 66 out of 100.
What is the most recent average sentiment for AKESO INC (AKESF:OTCMKTS)?
The most recent sentiment for AKESO INC (AKESF:OTCMKTS) is .
SEC-8K** Filing Available For AKESO INC (AKESF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.